Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 14Terminated 2Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 31Multiple Myeloma 30Prostatic Neoplasms 29Recurrence 28Stomach Neoplasms 27Pancreatic Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lung Neoplasms 26Carcinoma, Renal Cell 25Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Leukemia, Myeloid, Acute 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Lymphocytic, Chronic, B-Cell 19Glioblastoma 19Myelodysplastic Syndromes 17Uterine Cervical Neoplasms 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Leukemia 14

Interventions

binimetinib 1Imatinib Mesylate 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Gastrointestinal Stromal Tumors × Clear all
NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
75 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡